Clal Biotechnology Industries Ltd. (TASE: CBI) has filed confidentially with the US Securities and Exchange Commission for a special purpose acquisition company (SPAC) called Cactus Acquisition Corp. to raise $100 million in an IPO on Nasdaq. Cactus, a blank check company, would then seek an Israeli life sciences company to acquire or merge with.
RELATED ARTICLES
Clal Biotech, which has a market cap of NIS 390 million, is controlled by billionaire Len Blavatnik. Cactus is a partnership between Clal Biotech, a group led by UK billionaire Vincent Tchenguiz, and Israel Biotech Fund (IBF) headed by and managed by Yuval Cabilly, Prof. David Sidransky and Ido Zairi. Each partner will hold a 33.33% stake in Cactus, and the three partners will receive an overall 20% stake in the company that Cactus merges with.
Cactus chairman will be Homi Shamir, the former CEO of diagnostic pill company Given Imaging, which was sold to Covidien (since acquired by Medtronic) for $1 billion. Clal Biotech CEO Ofer Gonen will serve as CEO of Cactus, with management subsequently moving to the target company of the merger, which will have a valuation of several hundred million dollars.
Published by Globes, Israel business news – en.globes.co.il – on June 16, 2021
© Copyright of Globes Publisher Itonut (1983) Ltd. 2021
For all the latest Business News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
